The federal government has signalled fresh support for Pakistan’s pharmaceutical sector, with Finance and Revenue Minister Senator Muhammad Aurangzeb assuring industry leaders that key issues around pricing, regulation and investment will be examined carefully. The minister shared this message during a detailed meeting in Islamabad with a delegation of the Pharma Bureau, which represents leading multinational and local pharmaceutical companies operating in the country.
Pharma Bureau Briefs Government on Sector Performance
The delegation was led by Pharma Bureau Chairman Syed Anis Ahmed and included Co-chair Erum Shakir Rahim, Haleon Pakistan Limited Chief Executive Officer Qawi Naseer, Roche Pakistan Chief Executive Officer Hafsa Shamsi, Sajjad Iftikhar, Andleeb Ahmed and Pharma Bureau Executive Director Ayesha T. Haq. The group presented an overview of the sector’s performance in recent years, highlighting progress in regulatory processes, greater digitalisation and deeper engagement between regulators and industry stakeholders. They also pointed to ongoing efforts to move Pakistan’s drug regulator towards higher World Health Organization maturity levels, improve timelines for product approvals and support exports in a challenging macroeconomic environment.
Key Issues: Pricing, Availability and Regulatory Capacity
During the discussion, the Pharma Bureau representatives shared their views on a wide range of operational challenges. These included medicine pricing and availability, clarity and predictability in regulatory decision-making, and the need for more efficient investment facilitation. Taxation, incentives for research and innovation, and the export potential of high-quality pharmaceutical products were also raised. The delegation stressed that policy consistency and effective governance are essential for ensuring that patients continue to have reliable access to safe medicines. They argued that a stronger, better resourced regulator, aligned with international best practices, would benefit both public health and long-term investment in the sector.
Finance Minister Highlights Reform and Documentation Agenda
In response, Finance Minister Muhammad Aurangzeb acknowledged the vital contribution of the pharmaceutical industry to public health, job creation and overall economic activity. He briefed the delegation on the government’s wider economic reform agenda, which focuses on macroeconomic stabilisation, improving the tax system and expanding documentation across the economy. The minister underlined that creating a more predictable, rules-based environment is a key part of this strategy, and that the pharma sector is an important partner in achieving these goals. He also recognised the need to balance fiscal sustainability with timely decisions on pricing and other matters that directly affect patient access to essential medicines.
Commitment to Ongoing Engagement with Pharma Industry
Senator Aurangzeb assured the Pharma Bureau delegation that the issues and proposals raised in the meeting would be examined in detail in coordination with relevant ministries and regulatory bodies. He reaffirmed the government’s commitment to maintaining regular, structured engagement with industry stakeholders and extending facilitation within the framework of national priorities. Both sides agreed that continued dialogue and cooperation are necessary to address the sector’s challenges, build investor confidence and support sustainable growth. The meeting ended with an understanding that follow-up interactions will focus on practical solutions that keep patient welfare at the centre while enabling the pharmaceutical sector to innovate, expand exports and contribute more strongly to Pakistan’s economy.
For patients, doctors and businesses alike, the outcome of this engagement will be measured by whether policies on pricing, regulation and investment translate into steady supplies of quality medicines at affordable prices. The latest meeting between the Finance Minister and the Pharma Bureau is a signal that the federal government is willing to listen and work with the industry, but the real test will come in the months ahead as commitments are turned into concrete reforms and decisions.
